An Oversold Gold Miner With Strong Fundamentals--Its Relative Strength Index Is Below 20, And Its Piotroski F-Score Is 8
Portfolio Pulse from David Pinsen
A gold miner with strong fundamentals, including a Piotroski F-Score of 8 and a Relative Strength Index (RSI) below 20, is considered undervalued and a good buying opportunity. The miner has high margins, with all-in sustaining costs of about $700 per ounce, compared to an industry average of $1,360 per ounce. However, there is some political risk due to one of the company's properties being in a state in Mexico with a history of strikes. The SPDR Gold Shares ETF (GLD) and the VanEck Gold Miners ETF (GDX) are also mentioned in the context of gold and gold miners' performance.
October 05, 2023 | 1:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The VanEck Gold Miners ETF (GDX) is mentioned as a tracker of gold miners' performance. The ETF could see gains if gold prices increase and gold miners' profits rise.
The article suggests that if gold prices go up, gold miners' profits could see a significant increase, which would benefit GDX as it tracks the performance of gold miners.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
The SPDR Gold Shares ETF (GLD) is mentioned as a tracker of gold performance. The ETF could benefit if the Fed starts cutting rates and gold prices increase.
The article suggests that if the Fed starts cutting rates, gold prices could go up, which would benefit GLD as it tracks the performance of gold.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
NEUTRAL IMPACT
Biogen, Inc. (BIIB) is mentioned in the context of its recent acquisition of Reata Pharmaceuticals. The impact on BIIB's stock is not directly discussed in the article.
The article mentions BIIB's recent acquisition of Reata Pharmaceuticals, but does not discuss the impact of this acquisition on BIIB's stock.
CONFIDENCE 70
IMPORTANCE 30
RELEVANCE 30
NEUTRAL IMPACT
Reata Pharmaceuticals (RETA) is mentioned in the context of its recent acquisition by Biogen, Inc. The impact on RETA's stock is not directly discussed in the article.
The article mentions the recent acquisition of RETA by Biogen, Inc., but does not discuss the impact of this acquisition on RETA's stock.
CONFIDENCE 70
IMPORTANCE 30
RELEVANCE 30